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ABSTRACT Marek’s disease virus (MDV) causes deadly lymphoma and induces an
imbalance of the lipid metabolism in infected chickens. Here, we discovered that
MDV activates the fatty acid synthesis (FAS) pathway in primary chicken embryo ﬁ-
broblasts (CEFs). In addition, MDV-infected cells contained high levels of fatty acids
and showed increased numbers of lipid droplets (LDs). Chemical inhibitors of the FAS
pathway (TOFA and C75) reduced MDV titers by approximately 30-fold. Addition of the
downstream metabolites, including malonyl-coenzyme A and palmitic acid, completely
restored the inhibitory effects of the FAS inhibitors. Furthermore, we could demonstrate
that MDV infection activates the COX-2/prostaglandin E2 (PGE2) pathway, as evident by
increased levels of arachidonic acid, COX-2 expression, and PGE2 synthesis. Inhibition of
the COX-2/PGE2 pathway by chemical inhibitors or knockdown of COX2 using short hair-
pin RNA reduced MDV titers, suggesting that COX-2 promotes virus replication. Exoge-
nous PGE2 completely restored the inhibition of the COX-2/PGE2 pathway in MDV repli-
cation. Unexpectedly, exogenous PGE2 also partially rescued the inhibitory effects of FAS
inhibitors on MDV replication, suggesting that there is a link between these two path-
ways in MDV infection. Taken together, our data demonstrate that the FAS and COX-2/
PGE2 pathways play an important role in the replication of this deadly pathogen.
IMPORTANCE Disturbances of the lipid metabolism in chickens infected with MDV
contribute to the pathogenesis of disease. However, the role of lipid metabolism in
MDV replication remained unknown. Here, we demonstrate that MDV infection acti-
vates FAS and induces LD formation. Moreover, our results demonstrate that MDV rep-
lication is highly dependent on the FAS pathway and the downstream metabolites. Fi-
nally, our results reveal that MDV also activates the COX-2/PGE2 pathway, which
supports MDV replication by activating PGE2/EP2 and PGE2/EP4 signaling pathways.
KEYWORDS fatty acid synthesis, Marek’s disease virus, PGE2, avian viruses, virus
replication
Marek’s disease virus (MDV) is a highly oncogenic herpesvirus that infects chickensand causes deadly lymphoma. The virus is transmitted to naive chickens via the
respiratory tract. Macrophages or dendritic cells subsequently transfer the virus to the
major lymphoid organs, where it infects B and T cells (1). The infection of T cell subsets
plays a crucial role in MDV pathogenesis, while B cells are dispensable for this process
(2). CD4 T cells are the predominant cells for the establishment of MDV latency and
can be transformed, resulting in T cell lymphomas. T cells also transport the virus to the
feather follicle epithelia that produce infectious virus and shed it into the environment
(reviewed in reference 3). MDV has been shown to disturb the lipid metabolism of the
infected chickens, as it causes atherosclerotic plaque formation (4). Vaccination pre-
vents the development of these plaques (5). Lipid analysis of the arterial smooth
muscles from MDV-infected birds revealed a signiﬁcant increase in nonesteriﬁed fatty
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acids, cholesterol, cholesterol esters, squalene, phospholipids, and triacylglycerol. Fur-
thermore, excess lipid biosynthesis triggers cellular deposition of lipid droplets in
MDV-infected cells (4, 5). Despite these intriguing observations, the role of lipid
metabolism in MDV-infected cells remained unknown.
In fatty acid synthesis (FAS), acetyl-coenzyme A (CoA) is converted to malonyl-CoA
and subsequently to fatty acids. The ﬁrst step toward FAS is the conversion of citric acid
into acetyl-CoA by direct phosphorylation of ATP-citrate lyase (ACLY). The subsequent
committed step involves the conversion of acetyl-CoA into malonyl-CoA by acetyl-CoA
carboxylase (ACC). The ﬁnal step involves committed elongation by utilizing both
acetyl-CoA and malonyl-CoA coupled to the multifunctional fatty acid synthase (FASN)
to generate fatty acids (6). Dengue virus (DENV) (7), West Nile virus (WNV) (8) and
hepatitis C virus (HCV) (9) have been shown to preferentially enhance FASN activity and
fatty acid synthesis. Fatty acid can contribute to several key biological functions, such
as fatty acid oxidation (FAO), -oxidation, posttranslational modiﬁcation of proteins,
and generation of very-long-chain fatty acids. Prostaglandin E2 (PGE2), a potent lipid
modulator, is derived from enzymatic activity of inducible COX-2 on arachidonic acid
(AA). A direct association between induction of COX-2 activity and enhancement of
human cytomegalovirus (HCMV) replication has been reported (10, 11).
Here, we demonstrate that MDV infection activates both FAS and COX-2/PGE2
pathways, which are crucial for MDV replication. Interestingly, exogenous malonyl-CoA
and palmitic acid completely restore the inhibitory effects of FAS inhibitors on MDV
replication, suggesting that the synthetized fatty acids are crucial for MDV replication.
Intriguingly, addition of PGE2 partially restored the inhibitory effects of FAS inhibitors
on MDV replication, indicating that the two pathways are connected. Taken together,
our results demonstrate that FAS and PGE2 synthesis contribute to MDV replication.
(This article was submitted to an online preprint archive [12].)
RESULTS
Increased levels of lipid metabolites in MDV-infected cells. Relative production
of a panel of metabolites was determined in mock- and MDV-infected primary chicken
embryo ﬁbroblasts (CEFs) at 48 and 72 h postinfection (hpi) using two-dimensional gas
chromatography with mass spectrometry (GCGC-MS). The 16 lipid metabolites were
detected and analyzed. Eight lipid metabolites, including palmitic acid, were increased
at 72 hpi (Fig. 1A), 4 lipid metabolites showed no changes at any time point postin-
fection (Fig. 1B), and 4 lipid metabolites were decreased (Fig. 1C) at either 48 or 72 hpi.
Enhanced levels of fatty acids in the MDV-infected cells can be attributed to increase in
FAS and/or breakdown of lipids.
MDV replication depends on fatty acid synthesis. Here, we examined whether
MDV infection increases FAS. For a better understanding of FAS, a schematic illustration
of the FAS pathway is shown in Fig. 2A. Gene expression of the cellular enzymes
involved in the FAS pathway was analyzed in mock- and MDV-infected CEF cells using
quantitative PCR (qPCR). The results demonstrate that acetyl-CoA carboxylase (ACC)
and fatty acid synthase (FASN) genes were highly upregulated at 72 hpi (Fig. 2B).
Analysis of ACC protein levels in mock- and MDV-infected cells was performed using
Western blotting. The results demonstrate that the expression of ACC subunit 1 (62
kDa) (Fig. 2C) and FASN proteins (Fig. 2D) is increased in MDV-infected cells. Speciﬁc
chemical inhibitors for ACC (TOFA) and FASN (C75) were utilized to determine the role
of the FAS pathway in MDV replication. Nontoxic concentrations of TOFA, C75, or TOFA
and C75 (T/C) were determined based on viability and conﬂuence of the treated CEFs
(data not shown). At 72 hpi, viral titers were determined in the presence of the pharma-
cological inhibitors with addition of the exogenous downstream metabolites (malonyl-CoA
and palmitic acid). The inhibitors of ACC (TOFA; 1.54M) and FASN (C75; 5.9M) signiﬁ-
cantly reduced MDV titer by 27 (Fig. 2E)- and 28 (Fig. 2F)-fold, respectively. MDV titer was
further reduced when the cells were treated with nontoxic concentrations (data not shown)
of TOFA (1.54M) and C75 (5.9M) combined (T/C) compared to those of C75 or TOFA
alone (Fig. 2G). Therefore, we used T/C in some experiments to observe maximum inhib-
Boodhoo et al. Journal of Virology
July 2019 Volume 93 Issue 13 e00352-19 jvi.asm.org 2
 o
n






itory effects. Addition of malonyl-CoA to the culture in the presence of TOFA restored MDV
replication (Fig. 2H). Similarly, palmitic acid restored virus replication in the presence of C75
(Fig. 2I). Treatment of the cells with C75 or TOFA did not reduce plaque sizes (data not
shown). To conﬁrm the role of the FAS pathway in MDV replication, we also analyzed MDV
genome copy numbers at 72 hpi in the cells treated with TOFA or C75 using qPCR. The
results demonstrated that TOFA and C75 also reduce virus copy numbers (Fig. 2J), sug-
gesting that reduction in virus titer by TOFA or C75 is associated with virus copy numbers.
Taken together, the results demonstrate that MDV activates the FAS pathway and blocking
ACC and FASN decreases MDV titer, which can be rescued by the downstreammetabolites.
MDV infection increases the formation of neutral LDs. Lipid droplets (LDs) are
endoplasmic reticulum (ER)-derived organelles that consist of a neutral lipid core with
a phospholipid bilayer, and an increase in the number of LDs is an indication of
lipogenesis. Here, the role of FAS on lipid metabolism was evaluated in MDV-infected
cells based on LD formation. The presence of lipid droplets was examined in mock- and
MDV-infected CEFs using oil red O staining at 72 hpi (Fig. 3A). An increased accumu-
lation of LDs was observed in the MDV-infected cells (Fig. 3Ai) compared to that of the
mock-infected cells (Fig. 3Aii). To quantify the number of LDs, pRB1B UL35-GFP-infected
CEFs (488 nm) were stained with Red LipidTOX (568 nm), and LD formation was
analyzed using confocal microscopy. Larger numbers of LDs per cell were observed in
FIG 1 Alteration of fatty acid and arachidonic acid in MDV-infected CEFs. Metabolomics analysis of relative ratio (ratio of area to internal standard)
of lipid metabolites from mock (control; Con)- and MDV (RB1B; Inf)-infected CEFs are shown at 48 hpi and 72 hpi. Box and whisker plots show
minimum and maximum relative levels of named lipid metabolites that are increased (A), show no change (B), or are decreased (C) in
MDV-infected CEFs. Nonparametric Wilcoxon tests (Mann-Whitney) were used to assess normal distribution and test signiﬁcance, with the results
shown as means  SD. * (P 0.01), ** (P 0.001), and *** (P 0.0005) indicate a statistically signiﬁcant difference compared to the control. NS,
no signiﬁcant difference. The experiments were performed in biological triplicates with six technical replicates per biological replicate.
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MDV-infected cells than in the mock-infected cells, as determined using the IMARIS
software (P 0.0001) (Fig. 3B and C). Treatment of CEFs with TOFA or C75 decreases
(P 0.0001) the LD numbers per cell in MDV-infected cells (Fig. 3D). Altogether, these
data showed that MDV infection induced the accumulation of LDs and FAS inhibitors
reduced LD formation, indicating that there was a direct link between FAS and LD
formation in MDV infection.
MDV activates the COX-2/PGE2 pathway. LDs are reservoirs of COX-2 and the site
of PGE2 synthesis (13, 14) by which arachidonic acid (AA) can be converted into
eicosanoids, including PGE2, thromboxane A2 (TXA2), prostaglandin D2 (PGD2), prosta-
glandin I2 (PGI2), and prostaglandin F2 alpha (PGF2) (Fig. 4A). AA is converted from
elongation/desaturation of 18:3 -6 fatty acid, an essential fatty acid which can be freed
by lipases. In our experiments, we demonstrate that AA levels were elevated in the
MDV-infected CEFs (P 0.003) at 48 and 72 hpi (Fig. 1A). No signiﬁcant difference in
COX-1 mRNA transcript expression levels was observed between the mock- and
FIG 2 Fatty acid synthesis is involved in MDV replication in CEF cells. (A) Schematic FAS pathways highlighting the relevant pharmacological
inhibitors (red) and the respective enzymes (yellow box) as well as metabolites (green box). (B) Fold changes in gene expression in mock- or
MDV-infected CEF cells are shown at 24, 48, and 72 hpi. (C and D) Protein levels of ACC (C) and FASN (D) from mock- and MDV-infected CEFs at
72 hpi. (E to G) Alteration in MDV viral titer (PFU/ml) in MDV-infected CEFs treated with TOFA (0.03, 0.077, 0.154, 0.31, 0.77, and 1.54 M) (E), C75
(0.393, 1.97, 3.93, and 5.9 M) (F), and TOFA (1.54 M) (G) in combination with C75 (5.9 M) at 72 hpi are shown. (H and I) Analysis of MDV viral
titer (PFU/ml) in infected CEFs in the presence of malonyl-CoA (30, 25, 15, 10 and 5 M) with TOFA (1.54 M) (H) or palmitic acid with C75 (5.9 M)
(I). (J) MDV (RB1B) genome copy numbers per 104 cells (Meq gene with reference ovotransferrin gene) in the presence TOFA (1.54 M) or C75
(5.9 M) at 72 hpi. ** (P 0.01), *** (P 0.001), and **** (P 0.0001) indicate a statistically signiﬁcant difference compared to the control. NS, no
signiﬁcant difference. All viral titer experiments were performed in 6 replicates for plaque assays and 3 replicates for real-time PCR and Western
blot assays. The data are representative of 3 independent experiments.
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MDV-infected cells at 72 hpi using reverse transcription-PCR (RT-PCR). In contrast,
COX-2 mRNA transcripts (Fig. 4B) and protein levels (Fig. 4C) were increased in the
MDV-infected cells at 72 hpi. The expression levels of COX-2 in ﬁve independent
experiments are shown (Fig. 4D). Higher levels of PGE2 were detected in the superna-
tant of MDV-infected cells than in mock-infected cells at 72 hpi using a speciﬁc
enzyme-linked immunosorbent assay (ELISA) (Fig. 4E). Treatment of the cells with a
COX-2 inhibitor, SC-236, reduced MDV titer in a dose-dependent manner (Fig. 4F). To
conﬁrm the role of COX-2 in MDV replication, we also demonstrated that short hairpin
FIG 3 MDV infection increases the formation of neutral lipid droplets. (A) Visualization of cytoplasmic lipids in
neutral lipid droplet organelles of CEF cells in MDV-infected (i) and mock-infected (ii) cells (magniﬁcation, 10) at
72 hpi. Black arrows indicate lipid droplets. (B) Confocal microscopy imaging with maximum projection of z-stacks
for each channel demonstrating nuclear and cytoplasmic distribution of pRB1B UL35-GFP virus (green) and lipid
droplets (red). Mock- and pRB1B UL35-GFP-infected cells were ﬁxed at 72 hpi and stained with DAPI (nuclear stain)
and the neutral lipid stain LipidTOX-568nm. Images 5 and 10 are three-dimensional representative images analyzed
using IMARIS software. z-stacks were analyzed using the IMARIS spot function analysis tool to quantify the relative
amount of lipid droplets per cell in MDV-infected and mock-infected CEFs (50 to 90 cells). (C) The numbers of lipid
droplets per cell in MDV-infected and mock-infected CEFs at 72 hpi. (D) The numbers of lipid droplets per cell in
MDV-infected CEFs treated with TOFA (1.54 M) or C75 (5.9 M) are shown. ****, statistically signiﬁcant difference
compared to the control (P 0.0001). All experiments were performed in duplicates, and data are representative
of 3 independent experiments.
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FIG 4 MDV activates COX-2/PGE2 pathway. (A) Schematic pathway outlines the relevant pharmacological inhibitor (red) and the respective
enzyme (yellow box) as well as the metabolite (green box) studied within the eicosanoid biosynthesis pathway. (B) Fold change in expression of
upregulation of COX-2, but not COX-1, gene expression in MDV-infected CEFs at 72 hpi. (C) Western blot analysis showing relative COX-2 protein
expression in mock- and MDV-infected CEF cells at 72 hpi. (D) Relative ﬂuorescence representing the expression of COX-2 protein in mock- and
MDV-infected cells from ﬁve independent experiments at 72 hpi. Levels of -actin expression were used for normalization. (E) PGE2 (pg/ml)
concentrations in supernatant of mock- and MDV-infected CEF cells at 72 hpi. (F) MDV titer (PFU/ml) in the MDV-infected CEFs in the presence
of a COX-2 inhibitor, SC-236 (0.005, 0.025, 0.05, 0.1, and 0.25 g/ml). (G) Gel visualization of COX-2 gene silencing by shRNA compared to that
of scramble RNA in MDV-infected CEFs. -Actin was used as an internal control for each reaction. (H) CEFs transfected with shRNA targeting COX-2
silencing or control shRNA (scramble) compared to SC-236 (0.25 g/ml) at 72 hpi. (I) MDV titer (PFU/ml) in the MDV-infected CEFs treated with
SC-236 (0.25 g/ml) or in combination with PGE2 (5.0 g/ml), PGI2 (0.5 g/ml), PGD2 (0.5 g/ml), PGF2 (0.5 g/ml), and TXA2 (0.5 g/ml) at 72
hpi. (J and K) MDV titer in the presence of SC-236 (0.25 g/ml) and different concentrations of PGE2 (0.25, 0.5, 1.0, 2.5, and 5.0 g/ml) (J) or PGE2
(Continued on next page)
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RNA (shRNA) targeting COX-2 (Fig. 4 G) reduces MDV titers (Fig. 4H). Exogenous PGE2,
TXA2, PGD2, PGI2, or PGF2 was added to the cells treated with SC-236, and the results
demonstrated that PGE2 was the only prostanoid that rescued the inhibitory effects of
the COX-2 inhibitor on MDV titer (Fig. 4I). Exogenous PGE2 (0.1 to 5 g/ml) rescued the
inhibitory effects of SC-236 on MDV titer (Fig. 4J), while it did not alter MDV titer in the
absence of the COX-2 inhibitor (Fig. 4K). Strikingly, exogenous PGE2 also restored
the inhibitory effects of TOFA (Fig. 4L) or C75 (Fig. 4M) on virus titer, suggesting that
the inhibitory effect of FAS pathway inhibitors was at least partially dependent on
inhibition of PGE2 synthesis. Exogenous PGE2 recovered an MDV titer in the MDV-
infected cells treated with low (0.31 M), intermediate (0.77 M), or high (1.54 M)
concentrations of TOFA (Fig. 4L). Similarly, exogenous PGE2 rescued the inhibitory
effects of low (1.97 M) and high (5.9 M) concentrations of C75 on MDV titer (Fig. 4M).
To demonstrate that PGE2 does not block the function of TOFA and C75 on lipid
metabolism, the cells were treated with T/C in the presence or absence of PGE2
(5 g/ml), and the fold reduction in the numbers of lipid droplets per cell were analyzed
using confocal microscopy. The results demonstrated that the presence of PGE2 did not
affect the ability of T/C to reduce lipid droplet numbers (Fig. 4N).
PGE2 supports MDV replication through EP2 and EP4 receptors. In mammals,
PGE2 exerts its biological activities through prostaglandin receptors EP1 to EP4 (Fig. 5A).
Chicken EP2, EP3, and EP4 receptors have been cloned and characterized (15, 16), while
EP1 receptor has not yet been identiﬁed in chickens. Analysis of gene expression in the
mock- and MDV-infected CEFs demonstrated that the EP2 and EP4, but not EP3,
receptors were upregulated upon MDV infection (Fig. 5B), suggesting that PGE2 sup-
ported MDV replication through an EP2- and/or EP4-mediated mechanism. Receptor
antagonists for EP1 (SC-51322), EP2 (TG 4-155), and EP4 (ER-819762) were utilized to
examine the role of different EP receptors in MDV replication in vitro. As expected, the
EP1 receptor antagonist (SC-51322; 0.1, 1, 5, and 10 M) had no effect on MDV
replication (Fig. 5C). In contrast, TG 4-155 (2 and 4 M) (Fig. 5D) and ER-819762 (0.1, 0.5
and 1 M (Fig. 5E) reduced MDV titer (P 0.0001), suggesting that PGE2 supports MDV
replication through the EP2 and EP4 receptors. To conﬁrm these data, we also used an
shRNA system to downregulate the EP2 and EP4 receptors in CEFs (Fig. 4F). The results
demonstrate that RNA silencing of EP2 and EP4 by shRNAs and chemical inhibitors (TG
4-155, 4 M; ER-819762, 1.0 M) signiﬁcantly reduced total numbers of MDV plaques
(Fig. 5G). Taken together, our data indicate that virus-induced PGE2 synthesis supports
MDV replication through the EP2 and EP4 receptors.
DISCUSSION
MDV is an Alphaherpesvirus that infects chickens and causes a deadly lymphopro-
liferative disease. In addition to transformation of CD4 T cells, MDV causes athero-
sclerosis by disturbing the lipid metabolism in infected chickens (17), which can be
inhibited by vaccine-induced immunity (4, 18). MDV is a cell-associated virus, and
cell-free virus can only be produced by feather follicle epithelial cells in vivo. MDV is
transmitted to other chickens via inhalation of virus. No cell-free virus can be generated
in vitro, and surprisingly, little is known about the mechanism of MDV entry, replication,
and egress in vitro or in vivo. After infection of chickens, MDV can be detected in both
immune and nonimmune cells; however, the virus can only be detected in less than 2%
of CD4 T cells in the spleen. As there is no speciﬁc marker for identiﬁcation of
MDV-transformed T cells (3) and the majority of these cells undergo apoptosis even
following in vitro T cell activation, which can potentially modulate lipid metabolism,
FIG 4 Legend (Continued)
(0.25, 0.5, 1.0, 2.5, and 5.0 g/ml) without SC-236 (K) at 72 hpi. (L and M) MDV titer in the presence of different concentrations of TOFA (0.31, 0.77,
and 1.54 M) (L) or C75 (1.97, 3.93, and 5.9 M) (M) with and without exogenous PGE2 (5.0 g/ml) in the presence of SC-236, T/C, or vehicle at
72 hpi. (N) Fold reduction in numbers of lipid droplets per cell in response to TOFA (1.54 M) and C75 (5.9 M) in the presence or absence of
exogenous PGE2 (5.0 g/ml) at 72 hpi. * (P 0.01), ** (P 0.0022), *** (P 0.0007), and **** (P 0.0001) indicate statistically signiﬁcant
differences. NS, no statistical difference. Experiments were performed in 6 replicates for plaque assays and 3 replicates for real-time PCR, shRNA
silencing, Western blotting, and ELISAs. The data are representative of 3 independent experiments.
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analysis of MDV-induced lipid metabolism in primary lymphoma cells is highly chal-
lenging. Similarly, MDV can only be detected in less than 2% of MDV-transformed CD4
T cell lines (3), and lipid metabolism is highly activated in lymphoma cells. Therefore,
CEF cells represent more reproducible and reliable cells for studying the role of lipid
metabolism in MDV infection in an in vitro model. MDV infection can be readily
detected in the majority of primary CEF cells, which are the standard cells to investigate
the MDV replication cycle in vitro. Recently, an in vitro infection system for primary B
and T cells has been developed that we will also include in future studies (19).
Our analysis of MDV-infected CEFs demonstrates that MDV infection enhances the
expression of genes involved in FAS and increases the levels of AA, the prostaglandin
precursor. Our data suggest that MDV hijacks host metabolic pathways to provide
essential macromolecular synthesis to support infection and replication. De novo FAS
generates the metabolic intermediate acetyl-CoA, malonyl-CoA, and ﬁnally palmitate.
Targeted inhibition studies against the enzymes involved in FAS during infection have
yielded an alternative understanding of alteration of lipid metabolism in infections with
HCMV (20), Epstein-Barr virus (21), and HCV (22, 23). The ﬁrst step toward FAS is the
conversion of citric acid into acetyl-CoA by direct phosphorylation of ACLY. The
subsequent step involves the conversion of acetyl-CoA into malonyl-CoA by acetyl-coA
carboxylase (ACC) and ﬁnally elongation by utilizing both acetyl-CoA and malonyl-CoA
coupled to the multifunctional fatty acid synthase (FASN) to make fatty acids. Our
FIG 5 PGE2 supports MDV replication through EP2 and EP4 receptors. (A) Schematic pathway outlines the respective metabolites (green
box) and the relevant pharmacological inhibitor (red) that were used in this study to block prostaglandin receptors. (B) Fold change in
gene expression of PGE2 receptors EP2, EP3, and EP4 in MDV-infected CEFs at 72 hpi. (C to E) MDV titer in MDV-infected CEFs treated with
different concentrations of SC-51322 (EP1 antagonist; 0.1, 1, 5, and 10 M) (C), TG 4-155 (EP2 antagonist; 1, 2, and 4 M) (D), and
ER-819762 (EP4 antagonist; 0.1, 0.5, and 1.0 M) (E) at 72 hpi. (F) Gel visualization of EP2 and EP4 gene silencing by shRNA compared to
scramble RNA in MDV-infected CEFs. -Actin was used as an internal control for each reaction. (G) MDV titer (PFU/ml) in the MDV-infected
CEFs transfected with shRNA targeting EP2 and EP4 silencing or control shRNA (scramble) compared to TG 4-155 (4 M) and ER-819762
(1 M) at 72 hpi. ****, statistically signiﬁcant differences (P 0.0001). NS, no statistical difference. Experiments were performed in 6
replicates for plaque assays and 3 replicates for real-time PCR and gene silencing using shRNA. The data are representative of 3
independent experiments.
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results demonstrated that blocking ACC and FASN activity signiﬁcantly reduces MDV
replication, suggesting that MDV preferentially modulates the FAS pathway to generate
a variety of lipids that contribute to several key cellular processes. Our data conﬁrm that
the inhibitory effects of FAS inhibitors on MDV replication could be overcome by the
addition of palmitic acid, a metabolite downstream of FASN in the FAS pathway. This
indicates that inhibition of MDV by FAS inhibitors is not simply detrimental to the cell
but is essential for the production of infectious virus. There is very limited information
on the mechanism involved in alteration of cellular metabolism by viruses. There are
only two examples where the viral gene products necessary for changes in each speciﬁc
metabolic pathway have been identiﬁed (reviewed in reference 24). Similarly, there is
no information on the mechanism involved in activation of FAS by MDV. Interestingly,
MDV encodes a secreted glycoprotein, vLIP, which has homology with lipase but does
not have any enzymatic activity (25). Further research is required to determine the role
of MDV genes, including vLIP, in activation of lipid metabolism.
It is known that fatty acids are essential components for the initiation of key cellular
processes, such as membrane lipid synthesis, generation of LDs, and eicosanoid syn-
thesis (26). LDs are classically deﬁned as organelles with stored neutral lipids, and some
reports suggest that some viruses promote LD formation, which is involved in virus
replication and assembly (27–29). Our data demonstrate that MDV infection also increases
LD formation; however, the exact role of LDs in MDV infection is still unknown. LD
formation in MDV-infected cells is dependent on the FAS pathway, as FAS inhibitors
reduced the numbers of LDs. This organelle is a signiﬁcant source of triglyceride-derived
arachidonic acid (AA), reservoir of COX-2 and site of PGE2 synthesis (13, 14, 30). Our results
demonstrate that MDV infection increases the levels of FAS, AA, COX-2, and PGE2
synthesis; however, further studies are required to establish whether PGE2 synthesis
occurs in LDs of MDV-infected cells. Furthermore, our results conﬁrm previous obser-
vations on the role of FAS in LD formation, replication of pathogens, and PGE2 synthesis
(13). In MDV-infected cells, both metabolic and nonmetabolic factors could be involved
in COX-2 activation. Upregulation of COX-2 in the MDV-infected cells could be induced
by several mechanisms, including transforming growth factor beta (TGF-) (31, 32),
cyclic AMP (33), and activation of NF-B (34). Further studies are required to support the
role of these factors in the activation of COX-2 during MDV infection. COX-2-inducing
factors such as TGF- (32), which also activates fatty acid synthesis (31, 35), might be
involved in activation of COX-2 in MDV-infected cells. In fact, we have recently shown
that MDV infection increases the induction of TGF- in vivo (36); however, further
studies are required to examine the role of MDV-induced TGF- in the induction of
COX-2 during MDV infection. It has been shown that COX-2 in LDs, but not in
cytoplasm, is involved in PGE2 synthesis following infection or activation of the cells
(14). Further experiments are required to establish the role of FAS-induced LDs in the
activation of the COX-2/PGE2 pathway by MDV. Finally, we demonstrated that PGE2
promotes MDV replication via EP2 and EP4 receptors, which are upregulated in
MDV-infected cells. PGE2 can contribute to virus replication by inhibition of nitric oxide
production (37), type I interferon production (38), and modulation of immune cells,
including antigen-presenting cells and T cells (39). We have recently reported that
soluble factors released from MDV-transformed T cells inhibit the function of chicken T
cells in a COX-2-dependent manner (36). The proposed model for the role of FAS and
COX-2/PGE2 pathways in MDV infection is summarized in Fig. 6. This study has assisted
us in the identiﬁcation of potential pathways involved in MDV pathogenesis and may
eventually lead to the development of control measures. However, we do not antici-
pate the use of FAS inhibitors as an antiviral agent in poultry because of their systemic
side effects and potential residue in meat and eggs. Taken together, our results
demonstrate that MDV activates FAS and COX-2/PGE2 pathways, and replication of
MDV is dependent on PGE2 synthesis, which supports MDV infectivity through EP2 and
EP4 receptors.
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Ethics statement. Ten-day-old speciﬁc-pathogen-free embryonated chicken eggs (Valo Biomedia
GmbH) were used to generate primary chicken embryonic ﬁbroblast cells (CEFs). All embryonated
chicken eggs were handled in accordance with the guidance and regulations of Europe and the United
Kingdom Home Ofﬁce under project license number 30/3169. As part of this process, the work has
undergone scrutiny and approval by the ethics committee at The Pirbright Institute.
Chemicals and antibodies. Chemicals used include SB 204990 (Thermo Fisher Scientiﬁc, Paisley, UK),
TOFA, C75, cloﬁbrate, palmitic acid, and SC-236 (Sigma-Aldrich, Dorset, UK), PGD2, PGI2, and PGE2 (Cambridge
Bioscience, Cambridge, UK), and SC-51322, TG-4-155, and ER-819762 (Bio-Techne Ltd., Abingdon, UK), and all
were reconstituted in dimethyl sulfoxide. TXA2 (Cambridge Bioscience, Cambridge, UK) was reconstitute in
ethanol. PGF2 (Cambridge Bioscience, Cambridge, UK) and etomoxir and malonyl-CoA (Sigma-Aldrich,
Dorset, UK) were reconstituted in E199 medium. Anti--actin mouse monoclonal antibody (MAb), anti-FASN
goat polyclonal antibody (pAb), anti-COX2 goat pAb, and anti-ACC rabbit MAb (Abcam, Cambridge, UK) were
used for Western blot analysis. Donkey pAb to goat IgG, goat pAb to mouse IgG, and goat pAb to rabbit IgG
were also purchased from Abcam, Cambridge, UK.
CEF culture and plaque assay. CEFs were seeded at a rate of 1.5 105 cells/ml in 24-well plates in
E199 medium supplemented with 5% fetal calf serum (FCS), and virus titer was determined 72 h
postinfection with cell-associated MDV in the presence or absence of the inhibitors. To identify nontoxic
concentrations of the chemicals, mock- and MDV-infected CEFs were exposed to the chemicals or
vehicles, cell morphology and adherence/conﬂuence were monitored under light microscopy, and then
cells were stainedwith 7-AAD (BD Bioscience, Oxford, UK) and acquired usingMACSQuant ﬂow cytometry and
FlowJo software for analysis of the data. Nontoxic concentrations of the inhibitors and chemicals were
selected based on ﬂow cytometry data and conﬂuence. MDV-infected cells were titrated onto fresh CEFs, and
72 h postinfection, the cells were ﬁxed and incubated with mouse anti-gB MAb (clone HB-3), as previously
described (40), followed by horseradish peroxidase-conjugated rabbit anti-mouse Ig. After development of
the plaques using AEC substrate, the cells were washed with super Q water and viral plaques were counted
using a light microscope.
Metabolomics. CEFs were either mock infected or infected with the RB1B strain of MDV (100 PFU per
1.5 105 cells) in triplicates and harvested at 48 and 72 h postinfection (hpi). The levels of metabolites
were determined using GCGC-MS (Target Discovery Institute, University of Oxford), and the data were
analyzed as described previously (41). Those metabolites for which we had high conﬁdence in their
identiﬁcations are shown. The lipid proﬁles of mock- and MDV-infected cells were analyzed in biological
triplicates with up to six technical replicates per biological replicate. The data were adjusted and
normalized based on protein content. Virus infection did not change the size of the cells, as determined
by microscopy.
Knockdown of EP2, EP4, and COX-2 gene expression. Small short hairpin RNAs (shRNAs) and
control scrambled RNAs were designed using short interfering RNA (siRNA) Wizard software, and these
were chemically synthesized (InvivoGene, Toulouse, France) (Table 1). Construction of the shRNA
FIG 6 Schematic representation of the model. MDV systematically modulates cellular lipid metabolic
pathways to support its replication through FAS and COX-2/PGE2 pathways. (1) Infection of CEFs with
MDV results in an increase of de novo FAS pathway generation, which is required for MDV replication. (2)
Fatty acid can be stored in lipid droplet organelles as a site for eicosanoid biosynthesis. (3) Subsequently,
PGE2 is biosynthesized enzymatically from arachidonic acid by inducible COX-2. Signaling of PGE2 is
mediated through its EP2 and EP4 receptors in MDV-infected cells. Speciﬁc enzymes studied along the
pathway and their relative importance for MDV infection are highlighted in yellow. Major metabolites
which were identiﬁed as essential lipids are highlighted in green.
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harboring plasmid was performed per the manufacturer’s instructions. For silencing purpose, CEFs were
transfected with the silencing and scrambled plasmid backbone containing green ﬂuorescent protein
using Lipofectamine stem reagent (Life Technologies, Warrington, UK). The transfection efﬁciency was
observed at 24 h posttransfection using ﬂuorescence microscopy, and cells showing more than 70%
transfection efﬁciency were used for MDV infection.
qPCR to amplify MDV genes. DNA samples were isolated from 5 106 cells using the DNeasy-96
kit (Qiagen, Manchester, UK) according to the manufacturer’s instructions. A master mix was prepared
containing primers Meq-FP and Meq-RP (0.4 M), Meq probes (0.2 M), ovo forward and reverse primers
(0.4 M), and ovo probe (0.2 M; 5=Yakima Yellow-3=TAMRA; Eurogentec) and ABsolute Blue qPCR, low
Rox, master mix (Thermo Fisher Scientiﬁc, Paisley, UK). A standard curve generated for both Meq (10-fold
serial dilutions prepared from plasmid construct with Meq target) and the ovo gene (10-fold serial
dilutions prepared from plasmid construct with ovo target) were used to normalize DNA samples and to
quantify MDV genomes per 104 cells. All reactions were performed in triplicates to detect both Meq and
the chicken ovotransferrin (ovo) gene on an ABI7500 system (Applied Biosystems) using standard
conditions. MDV genomes were normalized and are reported as viral genome per 104 cells.
Real-Time PCR. Total RNA was extracted from mock- and MDV-infected CEFs using TRIzol (Thermo
Fisher Scientiﬁc, Paisley, UK) according to the manufacturer’s protocol and treated with DNA-free DNase.
Subsequently, 1 g of puriﬁed RNA was reverse transcribed to cDNA using a Superscript III ﬁrst-strand
synthesis kit (Thermo Fisher Scientiﬁc, Paisley, UK) and oligo(dT) primers according to the manufacturer’s
recommended protocol. The resulting cDNA was diluted 1 : 10 in diethyl pyrocarbonate-treated water.
Quantitative real-time PCR using SYBR green was performed on diluted cDNA using a LightCycler 480 II
(Roche Diagnostics GmbH, Mannheim, GER) as described previously (36). Data represent means from 6
biological replicates. The fold decreases in the mRNA transcript for EP2, EP4, and COX-2 genes were
detected by one-step RT-PCR performed with a Luna Universal one-step RT-qPCR kit (NEB) on an Applied
Biosystems 7500 qPCR system using primers outlined in Table 2.
Western blotting. Mock- and MDV-infected CEFs were lysed in radioimmunoprecipitation assay
buffer and quantiﬁed by spectrophotometry. The lysate was suspended in the Laemmli’s sample loading
buffer (Sigma-Aldrich, Dorset, UK) and loaded in 10% SDS-PAGE. After semidry transfer of SDS-PAGE on
a nitrocellulose membrane, the membrane was blocked in 5% skim milk powder for 2 h. The membranes
were incubated with primary antibody for 12 h at 4°C, washed, and incubated with secondary antibodies.
Finally, the blots were probed with the Odyssey CLx imaging system (Li-Cor, USA), and bands were
quantiﬁed with Image Studio Lite software.
Prostaglandin E2 ELISA. PGE2 was quantiﬁed in supernatant of mock- and MDV-infected cells using
a colorimetric assay (R&D Systems, Abingdon, UK) based on competition between unlabeled PGE2 in the
sample and a ﬁxed amount of conjugated PGE2. The assay was performed according to the recommen-
dations of the assay kit manufacturer. In brief, CEFs were either mock infected or infected with RB1B, and
the levels of PGE2 in the supernatant were determined at 72 hpi or the assay results were measured using
optical density at 450 nm. The concentrations of PGE2 were determined against a standard curve.
Oil red O staining. For analysis of lipid droplets, cell monolayer was washed with phosphate-
buffered saline (PBS) and ﬁxed with 4% formaldehyde for 30 min. Cells were subsequently stained with
oil red O solution for 30 min, followed by a wash in PBS. Cells were counterstained with hematoxylin for
3 min, followed by a wash with super Q water. Plates were visualized and imaged using a light microscope,
and the pictures were processed using Adobe Photoshop software.
TABLE 1 siRNA sequences against COX-2, EP2, and EP4




















aThe boldface at 5’ ends represents sequences for duplex stability, which provide resistance to RNase degradation. Boldface in the middle of a segment represents
the site for hairpin loop folding. Boldface at the 3’ region represent oligonucleotide overhangs, which are resistant to nuclease degradation.
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Fluorescence confocal microscopy. CEFs were seeded in 24-well plates that contained 12-mm-
diameter round coverslips at a rate of 1.0 105 cells per well. At 72 h after mock infection or infection
with the pRB1B UL35-GFP virus (the virus was kindly provided by V. K. Nair, The Pirbright Institute), the
samples were prepared for imaging. In brief, mock- or MDV-infected CEFs were ﬁxed with 4% formal-
dehyde for 30 min and incubated with HCS LipidTOX Red neutral lipid stain, and then nuclei were labeled
with 4=,6-diamidino-2-phenylindole (DAPI). Cells were viewed using a Leica SP2 laser-scanning confocal
microscope. The data are presented as maximum projections of z-stacks (23 to 25 sections; spacing,
0.3 mm), which were analyzed using IMARIS (Bitplane Scientiﬁc Software). Ninety MDV-infected cells and
40 mock-infected cells were analyzed, and their LipidTOX-labeled neutral lipid-containing organelles
were detected with the spot function of IMARIS. Images were processed using Adobe Photoshop
software.
Statistical analysis. All data are presented as means  standard deviations (SD) from at least three
independent experiments. Quantiﬁcation was performed using Graph Pad Prism 7 for Windows. The
differences between groups, in each experiment, were analyzed by nonparametric Wilcoxon tests
(Mann-Whitney) or by Kruskal-Wallis test (one-way analysis of variance, nonparametric). Results were
considered statistically signiﬁcant at a P value of 0.05 (*).
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